成纤维细胞生长因子受体
癌症研究
赫拉
成纤维细胞生长因子受体1
成纤维细胞生长因子受体3
膀胱癌
靶向治疗
成纤维细胞生长因子
生物
成纤维细胞生长因子受体4
生长因子受体
尿路上皮
成纤维细胞生长因子受体2
错义突变
碱性成纤维细胞生长因子
医学
成纤维细胞
移行细胞癌
癌症
癌变
内科学
受体
遗传学
克拉斯
结直肠癌
作者
Khaleel I. Al‐Obaidy,Liang Cheng C
标识
DOI:10.1136/jclinpath-2020-207115
摘要
Dysregulation of fibroblast growth factor receptors ( FGFRs ) has been implicated in several human malignancies, including urothelial carcinoma. In urothelial carcinoma, the oncogenic role of mutated FGFR is mediated by the RAS-mitogen-activated protein kinase pathway, resembling the effects observed with activated HRAS . Activating somatic mutations of FGFR3 are clustered in three hotspots in exons 7, 10 and 15, and are almost always missense mutations leading to amino acid substitution in the external, transmembrane or intracellular regions of the receptor. A fusion of FGFR3 to transforming acid coiled-coil containing protein 3, FGFR3 amplification and alternative splicing leading to aberrant FGFR3 activation are less common molecular alterations. In April 2020, the Food and Drug Administration (FDA) approved the first targeted FGFR therapy, erdafitinib, in patients with locally advanced or metastatic bladder cancer who have progressed on platinum-based chemotherapy. Herein, we reviewed the normal structure and function of FGFR . We also explored its role in the development of urothelial carcinoma and major developments in the FGFR -targeted therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI